Abstract
HIV replication can now be effectively suppressed using antiretroviral combination regimens. The search continues, however, for ways to restore the immune response and eliminate reservoirs of latent infection. Interleukin-2 (IL-2) may augment the immune response in HIV-infected persons. This article discusses the rationale for using IL-2 in those with HIV disease and reviews key trials of IL-2 treatment regimens.
MeSH terms
-
Antiretroviral Therapy, Highly Active
-
CD4 Lymphocyte Count
-
Dose-Response Relationship, Drug
-
HIV Infections / drug therapy
-
HIV Infections / immunology*
-
Humans
-
Immune System / drug effects*
-
Immunity / drug effects
-
Immunotherapy
-
Interleukin-2 / administration & dosage
-
Interleukin-2 / pharmacology
-
Interleukin-2 / therapeutic use*
-
Killer Cells, Natural / drug effects
-
Killer Cells, Natural / immunology
-
Receptors, Interleukin-2 / drug effects
-
Receptors, Interleukin-2 / immunology
-
Virus Latency / drug effects
-
Virus Latency / immunology
Substances
-
Interleukin-2
-
Receptors, Interleukin-2